Válvulas Cardíacas

5-HTP is the immediate precursor to serotonin, a neurotransmitter central to mood regulation. SAD is associated with reduced serotonin activity in winter, providing mechanistic rationale for 5-HTP supplementation. A double-blind NIMH study examined neuroendocrine responses to 200 mg oral 5-HTP in ten SAD patients versus controls. Multiple small clinical trials and open-label studies support modest antidepressant effects, though efficacy for SAD specifically is considered preliminary by NCCIH.

Catecholamine depletion studies demonstrate a specific link between reduced tyrosine availability and mood worsening in seasonal affective disorder (SAD). One study showed tyrosine boosted winter mood scores while placebo subjects declined sharply. The photoperiod-dependent sensitivity of the dopamine system provides a plausible mechanistic basis.

Cod liver oil addresses two converging drivers of seasonal mood decline: vitamin D deficiency (which peaks in winter) and omega-3 insufficiency. Large observational studies link CLO use with lower rates of depression in populations with limited winter sunlight. Seasonal affective disorder involves both nutrient deficiencies.

DHA is the primary structural omega-3 fatty acid in neuronal membranes and is specifically reported to be reduced in patients with seasonal winter affective disorder alongside EPA. While EPA drives more of the acute antidepressant effect in RCTs, DHA supports neuronal membrane fluidity, serotonin receptor density, and brain health relevant to seasonal mood. It is co-identified in studies documenting omega-3 deficits in SAD populations.

Omega-3 PUFAs including DHA have been studied in seasonal and broader mood disorders. Lower omega-3 status correlates with more severe seasonal affective disorder symptoms in observational data. DHA's effects on serotonin, neuroinflammation, and HPA axis regulation provide a mechanistic basis for seasonal mood support.

EPA's antidepressant mechanism is relevant to seasonal affective disorder (SAD) and seasonal mood decline, as SAD shares neuroinflammatory and serotonergic dysregulation pathways EPA targets. Clinical data are primarily extrapolated from EPA's broader antidepressant evidence base, with specific SAD investigation limited.

EPA is the omega-3 fatty acid most consistently linked to antidepressant effects in meta-analyses of RCTs and is specifically reported to be reduced in patients with seasonal winter affective disorder. Meta-analyses identify EPA (not DHA) as primarily responsible for omega-3 antidepressant efficacy. It acts via serotonin receptor sensitization and neuroinflammation suppression. Clinical doses of 1–2 g/day EPA have shown benefit for depressive mood in controlled trials.

Fish oil omega-3s have been investigated for seasonal affective disorder (SAD) given the established links between omega-3 status, mood regulation, serotonin metabolism, and inflammatory pathways implicated in depressive disorders. Population-level data show higher fish consumption correlates with lower rates of depression including seasonal forms. While specific SAD RCTs are limited, the broader antidepressant evidence base supports seasonal mood applications.

L-Tryptophan is an essential amino acid and the dietary precursor to serotonin, whose brain turnover is lowest in winter and directly correlated with sunlight duration. A published clinical trial directly compared L-tryptophan to placebo and evening light in 13 SAD sufferers, finding both L-tryptophan and light produced greater improvement than placebo. A 2015 PubMed review concluded that activation of serotonin synthesis with L-tryptophan alone or combined with light therapy could be effective in SAD.

Clinical trials of oral lavender oil preparation Silexan demonstrate significant antidepressant effects, including in mixed anxiety-depressive disorder. A meta-analysis found significant antidepressant effects of lavender in seven out of ten eligible trials. Silexan at 80 mg/day showed comparable efficacy to sertraline 50 mg/day in mild-to-moderate major depression.

A 2021 meta-analysis of 8 RCTs (n=569) found that lemon balm significantly reduced depression scores (SMD: −0.47) versus placebo. GABAergic, serotonergic (MAO-A inhibition), and cholinergic mechanisms underpin mood effects. While no trial has specifically targeted seasonal affective disorder, the herb's mood-lifting and anti-depressant effects in clinical trials are directly relevant to seasonal mood dips.

Magnesium is an essential mineral involved in over 300 enzyme reactions including serotonin synthesis, NMDA receptor regulation, and HPA axis stress response—all relevant to seasonal mood. Multiple peer-reviewed reviews and RCTs document magnesium's anxiolytic and antidepressant properties. A 2017 RCT (n=126) found 248 mg/day magnesium significantly reduced PHQ-9 depression scores. It is consistently listed among supplements relevant to mood disorders including SAD-related presentations.

Melatonin is a pineal hormone regulating circadian rhythms and sleep-wake cycles, both disrupted in SAD. The duration of nocturnal melatonin secretion increases in winter, and abnormal melatonin secretion has been observed in SAD patients. NCCIH specifically lists melatonin among complementary approaches reviewed for SAD, noting limited evidence that it improves sleep in SAD patients. It is also hypothesized as a chemical mediator of photoperiodic effects on seasonal mood.

Omega-3 fatty acids (EPA and DHA) are specifically reported to be reduced in the blood of patients with seasonal winter affective disorder. They modulate serotonin availability, neuronal membrane fluidity, and anti-inflammatory pathways implicated in mood. Small RCTs and epidemiological studies show mixed but occasionally positive results for general depression, with direct evidence of deficiency in SAD populations. EPA at 1–2 g/day is most consistently linked to antidepressant effects.

Rhodiola rosea is an adaptogenic plant traditionally used in Scandinavia and Russia for fatigue and depression, conditions associated with northern winters. It modulates serotonin, dopamine, norepinephrine, and beta-endorphins in mood-relevant brain regions. A 12-week RCT (n=57) found depression improvement comparable to sertraline. A systematic review of two RCTs (n=146) and seven open-label studies (n=714) concluded possible antidepressant action. It is specifically identified as relevant to stress-induced and lethargic/asthenic depression patterns that overlap with SAD.

Saffron (Crocus sativus) stigma extracts have been studied in more than 20 RCTs for mild-to-moderate depression. Meta-analyses confirm saffron significantly improves depressive symptoms versus placebo and shows comparable efficacy to pharmaceutical antidepressants. Its active constituents (crocin, safranal) modulate serotonin reuptake and reduce neuroinflammation. The largest RCT to date (n=128+, 2025) confirmed clinically significant improvements in depressive symptoms. Standard clinical dose is 30 mg/day of standardized extract.

SAMe is a naturally occurring methyl donor involved in serotonin and dopamine metabolism in the brain. It has been marketed in Europe as an antidepressant since the mid-1980s. A Cochrane review confirms SAMe has antidepressant efficacy; multiple RCTs support its use as both monotherapy and SSRI augmentation. It is specifically listed by pharmacist-oriented clinical sources among supplements studied for seasonal mood and SAD due to its role in neurotransmitter optimization.

Sceletium's serotonergic mechanism—SERT inhibition and monoamine release—is directly relevant to seasonal affective disorder (SAD), which is treated clinically with SSRIs and light therapy. No clinical trial has specifically evaluated sceletium in SAD patients, but the mechanistic parallel with established SAD pharmacotherapy supports this link.

St. John's Wort (Hypericum perforatum) has been directly studied in SAD clinical trials. A 1994 study (n=20) found significant reductions in depressive symptoms with Hypericum plus light therapy, and a 1999 RCT (n=168) found improvements with Hypericum alone comparable to Hypericum combined with light therapy. NCCIH acknowledges limited but present evidence for symptom improvement in SAD. Standardized extract is typically dosed at 300 mg (0.3% hypericin) three times daily.

Low serum vitamin D levels are commonly found in people with SAD and are directly associated with reduced sunlight exposure in winter. NCCIH explicitly lists vitamin D among complementary approaches studied for SAD. A 1999 trial (n=15) found vitamin D comparable to phototherapy; however, a 2014 RCT (n=34) and a 2006 RCT (n=2,117) failed to show significant benefit. Evidence is mixed, and NCCIH does not currently support vitamin D alone as an effective SAD treatment.

Vitamin D3 (cholecalciferol) is the endogenous form of vitamin D produced in skin via UVB and the primary supplemental form studied for SAD. Reduced winter sunlight causes declining vitamin D3 production, and low serum 25(OH)D is consistently associated with SAD. Clinical evidence parallels that for vitamin D broadly: mixed results across RCTs, with NCCIH not currently supporting D3 monotherapy as an effective SAD treatment.

Cocoa has a long traditional use as a mood-elevating food, especially during low-mood periods. Chocolate craving during winter months is culturally recognized, and cocoa contains neuroactive compounds (phenylethylamine, theobromine, serotonin precursors) that may support mood seasonally. Specific RCTs for seasonal mood disorder have not been conducted.

Damiana is used traditionally as a mood-lifter and mild antidepressant, and preclinical data show relevant neurochemical activity including MAO-B inhibition, dopamine reuptake inhibition, and anxiolytic effects. These mechanisms are relevant to seasonal mood changes. No seasonal affective disorder-specific studies exist.

Geranium EO is used in aromatherapy for mood elevation and emotional balance, including seasonal affective states. Its uplifting, antidepressant, and stress-reducing properties are recognized in herbal medicine. Evidence is extrapolated from RCTs on anxiety and depression rather than from seasonal mood-specific trials.

Ginkgo biloba has a long history of use in traditional Chinese medicine for supporting mental vitality, clarity, and emotional wellbeing across seasonal transitions. Modern interest stems from its monoamine-modulating properties and neuroprotective effects. However, dedicated clinical trials for seasonal mood support or seasonal affective disorder specifically are lacking.

Kanna's documented traditional role as a mood elevator and its SERT-inhibiting mechanism (directly relevant to seasonal affective disorder pharmacotherapy, which relies on SSRIs) provide a plausible but unvalidated basis for seasonal mood support. No clinical studies have specifically assessed kanna for seasonal affective disorder or winter mood changes.